Boston Family Office’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.23M | Sell |
16,037
-303
| -2% | -$42.4K | 0.15% | 114 |
|
|
2025
Q4 | $2.01M | Sell |
16,340
-900
| -5% | -$109K | 0.13% | 122 |
|
|
2025
Q3 | $1.92M | Hold |
17,240
| – | – | 0.12% | 125 |
|
|
2025
Q2 | $1.91M | Hold |
17,240
| – | – | 0.13% | 124 |
|
|
2025
Q1 | $1.93M | Hold |
17,240
| – | – | 0.14% | 113 |
|
|
2024
Q4 | $1.59M | Hold |
17,240
| – | – | 0.11% | 126 |
|
|
2024
Q3 | $1.45M | Hold |
17,240
| – | – | 0.1% | 133 |
|
|
2024
Q2 | $1.18M | Hold |
17,240
| – | – | 0.09% | 140 |
|
|
2024
Q1 | $1.26M | Hold |
17,240
| – | – | 0.09% | 136 |
|
|
2023
Q4 | $1.4M | Hold |
17,240
| – | – | 0.11% | 132 |
|
|
2023
Q3 | $1.29M | Hold |
17,240
| – | – | 0.11% | 129 |
|
|
2023
Q2 | $1.33M | Sell |
17,240
-300
| -2% | -$23.9K | 0.1% | 132 |
|
|
2023
Q1 | $1.46M | Sell |
17,540
-140
| -0.8% | -$11.6K | 0.12% | 124 |
|
|
2022
Q4 | $1.52M | Sell |
17,680
-2,300
| -12% | -$182K | 0.13% | 125 |
|
|
2022
Q3 | $1.23M | Sell |
19,980
-250
| -1% | -$15.8K | 0.11% | 131 |
|
|
2022
Q2 | $1.25M | Sell |
20,230
-200
| -1% | -$12.4K | 0.1% | 129 |
|
|
2022
Q1 | $1.22M | Sell |
20,430
-1,575
| -7% | -$101K | 0.09% | 143 |
|
|
2021
Q4 | $1.6M | Sell |
22,005
-3,905
| -15% | -$269K | 0.1% | 133 |
|
|
2021
Q3 | $1.81M | Sell |
25,910
-4,000
| -13% | -$281K | 0.13% | 123 |
|
|
2021
Q2 | $2.06M | Sell |
29,910
-1,225
| -4% | -$81.8K | 0.15% | 116 |
|
|
2021
Q1 | $2.05M | Sell |
31,135
-1,935
| -6% | -$125K | 0.15% | 114 |
|
|
2020
Q4 | $1.93M | Sell |
33,070
-4,390
| -12% | -$265K | 0.15% | 113 |
|
|
2020
Q3 | $2.37M | Sell |
37,460
-1,145
| -3% | -$79.4K | 0.21% | 96 |
|
|
2020
Q2 | $2.97M | Sell |
38,605
-43,398
| -53% | -$3.33M | 0.29% | 81 |
|
|
2020
Q1 | $6.13M | Sell |
82,003
-21,759
| -21% | -$1.5M | 0.72% | 44 |
|
|
2019
Q4 | $6.74M | Sell |
103,762
-2,048
| -2% | -$133K | 0.64% | 50 |
|
|
2019
Q3 | $6.71M | Sell |
105,810
-35
| -0% | -$2.29K | 0.7% | 49 |
|
|
2019
Q2 | $7.15M | Sell |
105,845
-868
| -0.8% | -$57.1K | 0.74% | 47 |
|
|
2019
Q1 | $6.94M | Sell |
106,713
-2,091
| -2% | -$139K | 0.75% | 48 |
|
|
2018
Q4 | $6.81M | Sell |
108,804
-1,216
| -1% | -$85K | 0.85% | 45 |
|
|
2018
Q3 | $8.49M | Sell |
110,020
-1,742
| -2% | -$132K | 0.9% | 36 |
|
|
2018
Q2 | $7.92M | Sell |
111,762
-2,276
| -2% | -$161K | 0.9% | 39 |
|
|
2018
Q1 | $8.6M | Sell |
114,038
-456
| -0.4% | -$36.2K | 0.98% | 33 |
|
|
2017
Q4 | $8.2M | Sell |
114,494
-95
| -0.1% | -$7.21K | 0.9% | 35 |
|
|
2017
Q3 | $9.28M | Sell |
114,589
-3,870
| -3% | -$296K | 1.05% | 25 |
|
|
2017
Q2 | $8.38M | Sell |
118,459
-10,421
| -8% | -$693K | 0.99% | 29 |
|
|
2017
Q1 | $8.75M | Sell |
128,880
-22,518
| -15% | -$1.58M | 1.08% | 30 |
|
|
2016
Q4 | $10.8M | Sell |
151,398
-15,110
| -9% | -$1.12M | 1.41% | 22 |
|
|
2016
Q3 | $13.2M | Sell |
166,508
-5,412
| -3% | -$440K | 1.71% | 12 |
|
|
2016
Q2 | $14.3M | Sell |
171,920
-1,222
| -0.7% | -$108K | 1.86% | 9 |
|
|
2016
Q1 | $15.9M | Sell |
173,142
-2,489
| -1% | -$224K | 2.1% | 5 |
|
|
2015
Q4 | $17.8M | Sell |
175,631
-1,597
| -0.9% | -$166K | 2.43% | 3 |
|
|
2015
Q3 | $17.4M | Sell |
177,228
-4,409
| -2% | -$490K | 2.42% | 4 |
|
|
2015
Q2 | $21.3M | Sell |
181,637
-6,308
| -3% | -$689K | 2.67% | 2 |
|
|
2015
Q1 | $18.4M | Sell |
187,945
-13,083
| -7% | -$1.33M | 2.29% | 3 |
|
|
2014
Q4 | $18.9M | Sell |
201,028
-2,635
| -1% | -$273K | 2.36% | 3 |
|
|
2014
Q3 | $21.7M | Sell |
203,663
-2,035
| -1% | -$199K | 2.79% | 2 |
|
|
2014
Q2 | $17.1M | Sell |
205,698
-1,098
| -0.5% | -$85.5K | 2.16% | 5 |
|
|
2014
Q1 | $14.7M | Sell |
206,796
-10,628
| -5% | -$834K | 1.95% | 5 |
|
|
2013
Q4 | $16.3M | Sell |
217,424
-4,936
| -2% | -$344K | 2.15% | 5 |
|
|
2013
Q3 | $14M | Sell |
222,360
-3,185
| -1% | -$190K | 1.99% | 8 |
|
|
2013
Q2 | $11.6M | Buy |
+225,545
| New | +$11.8M | 1.76% | 8 |
|
Other funds holding GILD
VCM
VPM
Boston Family Office's GILD Position: Q1 2026 in Review
Boston Family Office reduced its Gilead Sciences (GILD) stake by 1.9% in Q1 2026, selling an estimated $42.4K and leaving 16,037 shares worth $2.23M. The position accounts for 0.15% of the portfolio, ranked #114.
Boston Family Office first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $21.7M in Q3 2014. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Boston Family Office held 16,037 shares of Gilead Sciences worth $2.23M as of Q1 2026.
- Boston Family Office sold 303 Gilead Sciences shares in Q1 2026, an estimated $42.4K.
- Gilead Sciences made up 0.15% of Boston Family Office's portfolio in Q1 2026, its #114 holding.
- Boston Family Office first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
- Boston Family Office's Gilead Sciences position peaked at $21.7M in Q3 2014.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Boston Family Office's 13F filing for Q1 2026, filed 13 May 2026.